JFL Life SciencesNSE:JFLLIFE +1.44%67 PEG Ratio is 0.27 as of Jul. 12, 2026, which is 27% below its 10-year median of 0.37. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 67/100 and a GF Value™ of ₹35.85 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 348 Drug Manufacturers companies, JFL Life Sciences ranks better than 95.11% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for JFL Life Sciences's PEG Ratio or its related term are showing as below:
NSE:JFLLIFE'
s PEG Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.37 Max: 0.89
Current: 0.27
During the past 7 years, JFL Life Sciences's highest PEG Ratio was 0.89. The lowest was 0.22. And the median was 0.37.
NSE:JFLLIFE's PEG Ratio is ranked better than 95.11% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.665
vs NSE:JFLLIFE: 0.27
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
JFL Life Sciences (NSE:JFLLIFE) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
JFL Life Sciences PEG Ratio Related Terms
JFL Life Sciences PEG Ratio Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
JFL Life Sciences (NSE:JFLLIFE) has a PEG Ratio of 0.27 as of Jul. 12, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on JFL Life Sciences and its competitors. This is 27% below median its historical median of 0.37. Over the past decade, JFL Life Sciences' PEG Ratio has ranged from 0.22 to 0.89. According to the industry distribution chart, JFL Life Sciences ranks #17 out of 348 companies in the Drug Manufacturers industry, placing it in the top 4.9%.
Is JFL Life Sciences' PEG Ratio too high?
JFL Life Sciences' current PEG Ratio of 0.27 is 27% below median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 0.89. The Drug Manufacturers industry median PEG Ratio is 1.67. JFL Life Sciences' value of 0.27 is 83.8% below this industry median. Based on the distribution chart, JFL Life Sciences ranks #17 out of 348 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JFL Life Sciences has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #17 out of 348 companies for PEG Ratio. This places JFL Life Sciences in the top 5% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.67. JFL Life Sciences' value of 0.27 is 83.8% below this benchmark. Historically, JFL Life Sciences' own PEG Ratio has ranged from 0.22 to 0.89 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 1.67, JFL Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.67, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current PEG Ratio of 0.27 is 83.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current PEG Ratio is 0.27, which is 27% below median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.85, compared to a current price of ₹10.60 — trading 70.4% below its estimated fair value. The current PEG Ratio is 0.27, which is 27% below median its 10-year median of 0.37 and 83.8% below the Drug Manufacturers industry median of 1.67. JFL Life Sciences' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current PEG Ratio is 0.27 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.60 is trading 70.4% below its estimated GF Value™ of ₹35.85.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
PEG Ratio: 0.27 (27% below median its 10-year median of 0.37)
GF Value™: ₹35.85 vs. price of ₹10.60 (70.4% below fair value)
Industry Position: 83.8% below the Drug Manufacturers median (#17 of 348)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
67GF Score
Get the complete analysis for NSE:JFLLIFE
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 